Ascent Innovative Medicines Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
as on 17-12-2024
- Paid Up Capital ₹ 5.00 Cr
as on 17-12-2024
- Company Age 8 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 27.37%
(FY 2022)
- Profit 55.08%
(FY 2022)
- Ebitda 63.97%
(FY 2022)
- Net Worth -20.68%
(FY 2022)
- Total Assets -15.47%
(FY 2022)
About Ascent Innovative Medicines
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 5.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
Subodh Gupta and Suresh Deora serve as directors at the Company.
- CIN/LLPIN
U74900MH2016PTC273442
- Company No.
273442
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 Feb 2016
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Ascent Innovative Medicines?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Subodh Gupta  | Managing Director | 24-Feb-2016 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Suresh Deora | Director | 24-Feb-2016 | Current |
Financial Performance and Corporate Structure Insights of Ascent Innovative Medicines.
Ascent Innovative Medicines Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 27.37% increase. The company also saw a substantial improvement in profitability, with a 55.08% increase in profit. The company's net worth observed a substantial decline by a decrease of 20.68%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ascent Innovative Medicines?
In 2021, Ascent Innovative Medicines had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Ascent Innovative Medicines?
Ascent Innovative Medicines has a workforce of 8 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ascent Innovative Medicines, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ascent Innovative Medicines's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
